Prescription Drug Affordability Board Activity, January 2026
Activities Summary
Colorado: At its January meeting, the PDAB discussed ways to improve patient engagement and agreed to accept the dismissal of Amgen v. Mizner. The board's next meeting will be February 20, 2026.
Maryland: Maryland's next PDAB meeting will be February 23, 2026 at 9:00 AM ET.
Oregon: In January, Oregon's PDAB identified Cosentyx, Trulicity, and Vraylar as drugs that may create affordability challenges; discussed recommendations for their 2025 report; and began planning for 2026 affordability reviews. The next meeting is February 18, 2026.
Washington: Washington's PDAB will next meet on March 18, 2026.
Activity by State
Colorado
Colorado PDAB Meeting, January 9, 2026
Agenda | Recording | Slides | Written comment
Director update
Retiring PDAB Chair Gail Mizner thanked staff and stakeholders.
Board business - patient engagement
Staff and the chair of the Prescription Drug Affordability Advisory Council presented patient engagement strategies that emerged in the stakeholder workgroup meeting. Suggestions included developing a PDAB patient engagement toolkit with education materials, establishing a community partner network, and voluntary conflict of interest disclosures.
Public comment
Public comment included written submissions and Sophia Hennessy from Colorado Consumer Health Initiative.
Executive session
The board entered executive session to receive legal advice regarding the appeal of Amgen v. Mizner. They approved the dismissal of the appeal, publicly saying that they would save their resources for the next suit.
The next PDAB meeting will be February 20, 2026.
Oregon
Oregon PDAB Meeting, January 21, 2026
Public comment
Oregon’s PDAB received written public comments and heard oral public comments during the meeting from Dharia McGrew from PhARMA and Rainier Simons from the Community Access National Network made public comments.
2025 drug review
The board voted on the 23 drugs from the subset list that they reviewed throughout 2025, identifying Cosentyx, Trulicity, and Vraylar as drugs that may create affordability challenges for the healthcare system or high out-of-pocket costs for patients. During the initial vote, the board did not select any insulin product that may create an affordability challenge. After some discussion, Lantus Solostar was chosen to fulfill the statute.
Annual report and 2026 drug review
The board continued to discuss recommendations for the 2025 drug review report and the 2026 drug review roadmap. They also spoke about what the statute says about orphan drugs, clarifying that orphan drug exemptions are not drug-wide, but depend on the indication for use.
Staff presented the 2024 data they’ve put together so far for the 2026 reviews, highlighting changes made from the last reviews. The board discussed how to narrow drug lists for review. They agreed to begin by filtering out generics, antivirals, toxoids, and vaccines. Suggestions were also made to exclude Medicare Maximum Fair Price drugs.
The next board meeting will be February 18, 2026.